The ALDH9A1 antibody is a crucial tool for studying the aldehyde dehydrogenase 9 family member A1 (ALDH9A1), an enzyme involved in multiple metabolic pathways. ALDH9A1 catalyzes the oxidation of various aldehydes, including aminoaldehydes like γ-aminobutyraldehyde (to produce γ-aminobutyric acid, GABA) and betaine aldehyde (to synthesize glycine betaine), playing roles in neurotransmitter regulation, osmoprotection, and detoxification. It is expressed in tissues such as the liver, brain, and kidney, with subcellular localization in mitochondria and/or cytoplasm depending on isoform variants.
ALDH9A1 antibodies are designed to detect endogenous ALDH9A1 protein levels, aiding in research on its expression patterns, enzymatic activity, and physiological roles. These antibodies (monoclonal or polyclonal) are validated for techniques like Western blotting, immunohistochemistry, and immunofluorescence. Dysregulation of ALDH9A1 has been linked to disorders such as hyperprolinemia, cardiovascular diseases, and cancer, making its antibody valuable for exploring disease mechanisms.
Structurally, ALDH9A1 contains conserved aldehyde dehydrogenase domains, and antibodies often target epitopes within these regions to ensure specificity. Research using ALDH9A1 antibodies has shed light on its involvement in carnitine biosynthesis, choline metabolism, and potential interactions with other ALDH isoforms. Challenges include distinguishing ALDH9A1 from homologous family members, emphasizing the need for rigorous validation. Overall, ALDH9A1 antibodies are indispensable for elucidating its biological functions and therapeutic potential in metabolic and oxidative stress-related pathologies.